Inovio Pharmaceuticals, Inc. (INO)
NASDAQ: INO · Real-Time Price · USD
4.210
-0.140 (-3.22%)
Dec 3, 2024, 12:34 PM EST - Market open
Inovio Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 0.2 | 0.83 | 10.26 | 1.77 | 7.41 | 3.87 | Upgrade
|
| Other Revenue | - | - | - | - | - | 0.24 | Upgrade
|
| Revenue | 0.2 | 0.83 | 10.26 | 1.77 | 7.41 | 4.11 | Upgrade
|
| Revenue Growth (YoY) | -76.18% | -91.89% | 478.23% | -76.05% | 80.24% | -86.51% | Upgrade
|
| Cost of Revenue | 81.97 | 86.68 | 187.65 | 249.24 | 94.25 | 88.02 | Upgrade
|
| Gross Profit | -81.77 | -85.84 | -177.39 | -247.47 | -86.83 | -83.91 | Upgrade
|
| Selling, General & Admin | 39.64 | 47.58 | 76.19 | 53.75 | 37.25 | 27.2 | Upgrade
|
| Operating Expenses | 39.64 | 47.58 | 76.19 | 53.75 | 37.25 | 27.2 | Upgrade
|
| Operating Income | -121.41 | -133.43 | -253.57 | -301.22 | -124.08 | -111.11 | Upgrade
|
| Interest Expense | -0.46 | -1.22 | -1.25 | -1.94 | -8.7 | -7.95 | Upgrade
|
| Interest & Investment Income | 5.73 | 8.13 | 4.78 | 3.36 | 3.31 | 2.61 | Upgrade
|
| Earnings From Equity Investments | -0.35 | 0.77 | -4.06 | -0.99 | 31.97 | -3.09 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.09 | 0.09 | 0.17 | 0.35 | -75.79 | -1.74 | Upgrade
|
| EBT Excluding Unusual Items | -116.39 | -125.65 | -253.94 | -300.43 | -173.29 | -121.29 | Upgrade
|
| Impairment of Goodwill | - | -10.51 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 1.53 | 1.04 | -11.88 | -3.23 | 1.11 | 0.48 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | 4.12 | - | Upgrade
|
| Legal Settlements | - | - | -14 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | - | 0.58 | - | Upgrade
|
| Pretax Income | -112.88 | -135.12 | -279.82 | -303.66 | -167.47 | -120.81 | Upgrade
|
| Income Tax Expense | - | - | - | - | - | -0.26 | Upgrade
|
| Earnings From Continuing Operations | -112.88 | -135.12 | -279.82 | -303.66 | -167.47 | -120.55 | Upgrade
|
| Minority Interest in Earnings | - | - | - | - | 1.06 | 1.19 | Upgrade
|
| Net Income | -112.88 | -135.12 | -279.82 | -303.66 | -166.41 | -119.36 | Upgrade
|
| Net Income to Common | -112.88 | -135.12 | -279.82 | -303.66 | -166.41 | -119.36 | Upgrade
|
| Shares Outstanding (Basic) | 25 | 22 | 20 | 17 | 13 | 8 | Upgrade
|
| Shares Outstanding (Diluted) | 25 | 22 | 20 | 17 | 13 | 8 | Upgrade
|
| Shares Change (YoY) | 16.75% | 11.51% | 14.27% | 34.62% | 57.14% | 6.68% | Upgrade
|
| EPS (Basic) | -4.45 | -6.09 | -14.07 | -17.45 | -12.87 | -14.51 | Upgrade
|
| EPS (Diluted) | -4.45 | -6.09 | -14.07 | -17.45 | -12.87 | -14.51 | Upgrade
|
| Free Cash Flow | -111.18 | -124.69 | -217.18 | -216.94 | -179.5 | -98.84 | Upgrade
|
| Free Cash Flow Per Share | -4.39 | -5.62 | -10.92 | -12.47 | -13.89 | -12.01 | Upgrade
|
| Operating Margin | -59685.24% | -16036.67% | -2470.93% | -16972.34% | -1674.25% | -2702.10% | Upgrade
|
| Profit Margin | -55491.09% | -16239.87% | -2726.67% | -17109.87% | -2245.39% | -2902.75% | Upgrade
|
| Free Cash Flow Margin | -54655.44% | -14986.17% | -2116.34% | -12223.61% | -2422.00% | -2403.69% | Upgrade
|
| EBITDA | -119.5 | -130.66 | -249.42 | -297.66 | -120.5 | -106.44 | Upgrade
|
| D&A For EBITDA | 1.91 | 2.77 | 4.15 | 3.56 | 3.59 | 4.66 | Upgrade
|
| EBIT | -121.41 | -133.43 | -253.57 | -301.22 | -124.08 | -111.11 | Upgrade
|
| Revenue as Reported | - | - | - | - | - | 4.11 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.